Clinical Trial Update: Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial exploring Envafolimab plus chemotherapy as neoadjuvant and conversion therapy for head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Envafolimab (envafolimab)

Snippet

Sponsor: Hairong Liu | Conditions: Efficacy and Safety | Phase 2 | Status: UNKNOWN